渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

盘前交易 05-02 06:42:31 EDT

216.13

+1.31

+0.61%

盘前216.06

-0.07-0.03%

06:37 EDT

最高218.66	最低214.70	成交量91.64万
今开215.56	昨收214.82	日振幅1.84%
总市值314.68亿	流通市值313.50亿	总股本1.46亿
成交额1.98亿	换手率0.63%	流通股本1.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":216.13,"timestamp":1714593600000,"preClose":214.82,"halted":0,"volume":916370,"hourTrading":{"tag":"盘前","latestPrice":216.06,"preClose":216.13,"latestTime":"06:37 EDT","volume":2,"amount":432.12,"timestamp":1714646240057},"delay":0,"floatShares":145050280,"shares":145596895,"eps":8.003279,"marketStatus":"盘前交易","marketStatusCode":1,"change":1.31,"latestTime":"05-02 06:42:31 EDT","open":215.56,"high":218.66,"low":214.7,"amount":198431886.93510002,"amplitude":0.018434,"askPrice":216.58,"askSize":2,"bidPrice":216,"bidSize":1,"shortable":3,"etf":0,"ttmEps":8.003279,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714656600000},"adr":0,"listingDate":685080000000,"adjPreClose":216.13,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":216.06,"preClose":216.13,"latestTime":"06:37 EDT","volume":2,"amount":432.12,"timestamp":1714646240057},"postHourTrading":{"tag":"盘后","latestPrice":217.58,"preClose":216.13,"latestTime":"18:45 EDT","volume":43596,"amount":9423076.09,"timestamp":1714603537788},"volumeRatio":0.4561899809304996,"optionData":{"bulkOrders":[{"symbol":"BIIB","call":false,"expireDate":1718942400000,"strike":"280.0","timestamp":1714591094921,"price":61.599998474121094,"volume":1010,"amount":6221600,"type":"-"}]}},"requestUrl":"/m/hq/s/BIIB/","defaultTab":"news","newsList":[{"id":"2431947815","title":"奥本海默：维持Biogen(BIIB.US)评级，由优于大市调整至优于大市评级, 目标价由270.00美元调整至270.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2431947815","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431947815?lang=zh_cn&edition=full","pubTime":"2024-04-30 00:55","pubTimestamp":1714409713,"startTime":"0","endTime":"0","summary":"奥本海默：维持Biogen(BIIB.US)评级，由优于大市调整至优于大市评级, 目标价由270.00美元调整至270.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300055168b62e662&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300055168b62e662&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430304972","title":"巴克莱：维持Biogen(BIIB.US)评级，由持股观望调整至持股观望评级, 目标价由215.00美元调整至200.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2430304972","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430304972?lang=zh_cn&edition=full","pubTime":"2024-04-26 02:15","pubTimestamp":1714068919,"startTime":"0","endTime":"0","summary":"巴克莱：维持Biogen(BIIB.US)评级，由持股观望调整至持股观望评级, 目标价由215.00美元调整至200.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260215248b53f356&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260215248b53f356&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430239165","title":"渤健公司2024财年第一财季实现净利润3.93亿美元，同比增加1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430239165","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430239165?lang=zh_cn&edition=full","pubTime":"2024-04-26 00:18","pubTimestamp":1714061915,"startTime":"0","endTime":"0","summary":"3月31日，渤健公司公布财报，公告显示公司2024财年第一财季净利润为3.93亿美元，同比增加1.29%；其中营业收入为22.00亿美元，同比减少5.62%，每股基本收益为2.71美元。从资产负债表来看，渤健公司总负债113.55亿美元，其中短期债务2.50亿美元，资产负债比为2.34，流动比率为2.10。机构评级：截至2024年3月31日，当前有28家机构对渤健公司目标价做出预测，其中目标均价为287.25美元，其中最低目标价为200.00美元，最高目标价为350.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260018408b53b360&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260018408b53b360&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430284766","title":"渤健公司跌1.01% 股价跌破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2430284766","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430284766?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:15","pubTimestamp":1714054529,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日22时15分，渤健公司股票出现波动，股价快速跳水1.01%。渤健公司股票所在的制药行业中，整体跌幅为0.59%。渤健公司公司简介：Biogen Inc和Idec于2003年合并，联手销售Biogen的多发性硬化症药物Avonex和Idec的癌症药物Rituxan。市场分析人士普遍认为，渤健公司在多个治疗领域的突破性成果，是本次Canaccord Genuity上调其目标价的关键因素。此外，渤健公司近期良好的财报表现，也为其股价提供了有力支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240425221530861e916f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240425221530861e916f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430643427","title":"渤健公司：目标价上调至308美元，Canaccord Genuity看好其潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2430643427","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2430643427?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:31","pubTimestamp":1714030305,"startTime":"0","endTime":"0","summary":"快讯正文4月25日，加拿大投资银行Canaccord Genuity对渤健公司的目标价进行了调整，由之前的305美元提升至308美元。市场分析人士普遍认为，渤健公司在多个治疗领域的突破性成果，是本次Canaccord Genuity上调其目标价的关键因素。此外，渤健公司近期良好的财报表现，也为其股价提供了有力支撑。Canaccord Genuity的此次调整，无疑为二级市场投资者提供了积极信号。在当前市场环境下，渤健公司的股价表现和未来发展潜力，无疑将成为投资者关注的焦点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042515454187ae197e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042515454187ae197e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430465869","title":"嗡嗡声--美国股票走势-MSCI、环球人寿、EQT Corp","url":"https://stock-news.laohu8.com/highlight/detail?id=2430465869","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430465869?lang=zh_cn&edition=full","pubTime":"2024-04-25 00:16","pubTimestamp":1713975398,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      4月24日 - 纳斯达克指数周三涨幅超过华尔街同行，特斯拉在发布季度财报后领涨超级大盘股，而其他行业乐观的财报也为纳斯达克指数提供了支撑。美东时间11:31，道琼斯工业平均指数  下跌0.35%，报38368.64点。标准普尔500指数  下跌0.15%，报5063.11点；纳斯达克综合指数  上涨0.16%，报15721.85点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429456655","title":"嗡嗡声--美国股票走势-百健、Humana、金矿企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2429456655","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429456655?lang=zh_cn&edition=full","pubTime":"2024-04-24 21:28","pubTimestamp":1713965311,"startTime":"0","endTime":"0","summary":"标准普尔500指数小型股  上涨0.08%，报5110.5点；纳斯达克100指数小型股  上涨0.52%，报17698.75点。** 巴里克黄金公司  ：盘前下跌0.4** AngloGold Ashanti Ltd   ：盘前下跌 1.7** Sibanye Stillwater Ltd   ：盘前下跌2.1%BUZZ - Gold miners fall as fears of wider Middle East crisis ease   ** Humana Inc   ：盘前上涨1.9%BUZZ--因医疗保险实力增强，第一季度利润超预期而上涨   ** Vertiv Holdings Co   ：盘前上涨 17.2%BUZZ - 因年度预期提升而上涨   ** Bunge Global SA   ：盘前下跌4.8%BUZZ - 因第一季度销售不佳而下跌   ** Amneal Pharmaceuticals Inc   ：盘前上涨10.2%BUZZ--因FDA批准非处方用药过量逆转鼻喷雾剂而上涨","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429568974","title":"BUZZ-由于合作伙伴百健公司产后抑郁症药物第一季度销售强劲，赛捷公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2429568974","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429568974?lang=zh_cn&edition=full","pubTime":"2024-04-24 21:25","pubTimestamp":1713965135,"startTime":"0","endTime":"0","summary":"** 合作伙伴百健  公布第一季度产后抑郁症药物Zurzuvae的收入为1200万美元** 至少有三位分析师表示 Zurzuvae 的销售额超出了他们的预期 ** 杰富瑞分析师迈克尔-易说，Zurzuvae的销售额超出预期表明，该药的上市可能比预期的要好。** 该药于去年8月被批准用于治疗成人产后抑郁症  ** BIIB的第一季度利润也高于预期，与日本制药商卫材  合作的阿尔茨海默氏症药物Leqembi的全球销售额达到1900万美元。** 截至上次收盘，BIIB 股价下跌 25.4%，SAGE 累计下跌 40","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429913437","title":"成本削减措施生效，渤健公司Q1盈利超过预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2429913437","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429913437?lang=zh_cn&edition=full","pubTime":"2024-04-24 20:05","pubTimestamp":1713960300,"startTime":"0","endTime":"0","summary":"其新的阿尔茨海默氏症药物Leqembi势头强劲。","market":"us","thumbnail":"https://static.tigerbbs.com/480143a3139433a7b4c7760557612e94","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/480143a3139433a7b4c7760557612e94"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"db281c116d914585a115ec9827470da2","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109011.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2429434752","title":"BUZZ-百健因第一季度利润超预期、阿尔茨海默氏症药物销量激增而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2429434752","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429434752?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:38","pubTimestamp":1713958695,"startTime":"0","endTime":"0","summary":"    4月24日 - ** 百健  股价盘前上涨3.6%，报200.11美元 ** 制药公司第一季度每股收益超出预期，阿尔茨海默氏症药物Leqembi的全球销售额几乎是第四季度的三倍，达到1900万美元** 补充说，从 2023 年底开始，Leqembi 的患者人数将增加 2.5 倍，但没有给出具体数字** 百健公司与日本卫材公司  合作开发Leqembi，他们的目标是到2026年让10万名患者使用Leqembi。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429360574","title":"百健公司季度利润超出预期，阿尔茨海默氏症药物销售额大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2429360574","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429360574?lang=zh_cn&edition=full","pubTime":"2024-04-24 18:45","pubTimestamp":1713955503,"startTime":"0","endTime":"0","summary":"在多发性硬化症药物和脊髓性肌肉萎缩症治疗药物面临日益激烈的竞争之际，百健公司正指望新药来推动未来几年的增长，其中包括第二个获批的阿尔茨海默氏症药物Leqembi。百健曾经的多发性硬化症治疗药物 Tecfidera 面临着廉价仿制药的竞争，其季度销售额为2.543 亿美元，高于预期的 2.3684 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429929534","title":"百健公司  预计每股收益3.44美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429929534","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429929534?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:23","pubTimestamp":1713792191,"startTime":"0","endTime":"0","summary":"   * LSEG 分析师对百健公司的平均预期为每股收益 3.44 美元。* 华尔街对百健公司 12 个月目标价的中位数为 288.50 美元，高于其最后收盘价 194.38 美元。4月22日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":1},{"id":"2428668911","title":"美国研究综述-Blackstone、Ellington Financial、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2428668911","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428668911?lang=zh_cn&edition=full","pubTime":"2024-04-19 15:24","pubTimestamp":1713511479,"startTime":"0","endTime":"0","summary":"    路透社4月19日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括黑石集团、艾灵顿金融公司和 Netflix。要闻              * 黑石集团  ：Piper Sandler 将目标价从 146 美元下调至 143 美元             * Ellington Financial Inc   ：Jonestrading 给予其 \"持有 \"评级             * Netflix Inc   ：Pivotal Research将目标价从765美元上调至800美元 以下是路透社周五报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426257723","title":"小摩：维持Biogen(BIIB.US)评级，由中性调整至中性评级, 目标价由270.00美元调整至240.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426257723","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426257723?lang=zh_cn&edition=full","pubTime":"2024-04-11 20:55","pubTimestamp":1712840125,"startTime":"0","endTime":"0","summary":"小摩：维持Biogen(BIIB.US)评级，由中性调整至中性评级, 目标价由270.00美元调整至240.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404112055288b106616&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404112055288b106616&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426284371","title":"美国研究综述-Airbnb、Albemarle、Biogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2426284371","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426284371?lang=zh_cn&edition=full","pubTime":"2024-04-11 15:32","pubTimestamp":1712820730,"startTime":"0","endTime":"0","summary":"    路透社4月11日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括 Airbnb、Albemarle 和 Biogen。* Aflac Inc   ：杰富瑞将目标价从 83 美元上调至 84 美元             * Airbnb Inc   ：Benchmark给予买入评级，目标价190美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":1},{"id":"2424079470","title":"BUZZ-百健因阿尔茨海默氏症皮下注射药物Leqembi申请延迟而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2424079470","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2424079470?lang=zh_cn&edition=full","pubTime":"2024-04-01 18:59","pubTimestamp":1711969146,"startTime":"0","endTime":"0","summary":"    4月1日 - ** 百健  股价盘前下跌1.25%至212.94美元** 该公司的合作伙伴卫材  表示， ，阿尔茨海默氏症药物Leqembi的皮下注射形式的 监管申请被推迟。** 卫材的目标是在上个月提交皮下注射每周维持疗法的上市申请。** 卫材原计划在 FDA 快速通道指定的滚动审查期间提供这些数据，但皮下注射制剂不具备这一条件。** Leqembi 的静脉注射剂型去年获得了 FDA 的标准批准  ** 截至上日收盘，BIIB股价年累计下跌约17%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421818870","title":"欧盟药品监管机构本周未讨论百健(BIIB.US)与卫材(ESALY.US)旗下阿尔茨海默病药物Leqembi","url":"https://stock-news.laohu8.com/highlight/detail?id=2421818870","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2421818870?lang=zh_cn&edition=full","pubTime":"2024-03-22 20:31","pubTimestamp":1711110718,"startTime":"0","endTime":"0","summary":"欧洲药品管理局此前曾表示，本周将举行口头听证会，以讨论百健及其日本合作伙伴卫材共同开发的阿尔茨海默病治疗药物Leqembi(通用名：lecanemab-irmb)。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20240322/20240322203213_90972.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240322/20240322203213_90972.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1090809.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421575896","title":"更新版 1-欧盟药品监管机构未在会议记录中提及卫材-百健的阿尔茨海默氏症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2421575896","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421575896?lang=zh_cn&edition=full","pubTime":"2024-03-22 19:05","pubTimestamp":1711105550,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (添加背景信息)    路透社3月22日 - 欧盟药品监管机构周五在其说明和建议中没有提及卫材  和百健  的阿尔茨海默氏症药物。 欧洲药品管理局曾表示将在本周举行口头听证会，讨论这种名为lecanemab的药物。 该药在美国以Leqembi的名义销售，自2023年1月起在欧洲接受审查。该药去年在美国获得传统批准，并在中国和日本等其他国家获得批准。 这种药物每月输注两次，可以清除大脑中被认为是阿尔茨海默氏症标志的淀粉样β蛋白的粘性团块。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2418061964","title":"BUZZ-美国食品及药物管理局推迟阿尔茨海默氏症药物决策后，礼来公司股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2418061964","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2418061964?lang=zh_cn&edition=full","pubTime":"2024-03-09 00:25","pubTimestamp":1709915155,"startTime":"0","endTime":"0","summary":" (更新)    3月8日 - ** 制药商礼来  股价下跌1.3%至766.17美元** 该公司称， ，美国食品和药物管理局已推迟就其针对早期阿尔茨海默病患者的实验性治疗药物多那尼单抗做出决定，并将召开外部专家会议讨论该药物的安全性和有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417374070","title":"BUZZ-礼来因美国食品及药物管理局推迟阿尔茨海默氏症药物决策而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2417374070","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417374070?lang=zh_cn&edition=full","pubTime":"2024-03-08 19:59","pubTimestamp":1709899149,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    3月8日 - ** 制药商礼来  股价盘前下跌近1.2%，至771.06美元** 称 (link)，美国食品和药物管理局（FDA）已推迟决定是否批准其针对早期阿尔茨海默病患者的实验性疗法多那尼单抗，并将召开外部专家会议讨论该疗法的安全性和有效性。** 称咨询委员会会议的日期尚未确定，但可能会在几个月后召开** Donanemab将与卫材  和百健公司<Biogen BIIB.O>的Leqembi竞争。** 百健公司股价在收盘前上涨了 3.7%，报 227 美元。** 截至上次收盘，LLY 的股价在过去 12 个月里上涨了一倍多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com","stockEarnings":[{"period":"1week","weight":0.07},{"period":"1month","weight":0.0061},{"period":"3month","weight":-0.1279},{"period":"6month","weight":-0.1337},{"period":"1year","weight":-0.3012},{"period":"ytd","weight":-0.1648}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1511},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，他们收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学；阿尔茨海默病（AD）和痴呆症；神经肌肉疾病，包括脊髓肌萎缩症（SMA）和肌萎缩侧索硬化症（ALS）；运动障碍，包括帕金森氏症；以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.575758,"avgChangeRate":0.042714},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.004267},{"month":3,"riseRate":0.515152,"avgChangeRate":-0.023197},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.018344},{"month":5,"riseRate":0.606061,"avgChangeRate":0.030979},{"month":6,"riseRate":0.46875,"avgChangeRate":0.017689},{"month":7,"riseRate":0.6875,"avgChangeRate":0.038795},{"month":8,"riseRate":0.59375,"avgChangeRate":0.032796},{"month":9,"riseRate":0.5,"avgChangeRate":0.024456},{"month":10,"riseRate":0.545455,"avgChangeRate":0.062497},{"month":11,"riseRate":0.606061,"avgChangeRate":0.016153},{"month":12,"riseRate":0.484848,"avgChangeRate":0.038726}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}